Member Info for crumbs

Yeah well, us long-termers and I'm not the longest! Have been through it ... I missed the 60p hurrah of here is moditope 'spike' but for sure I was caught on the dragged out comedown... that is AIM , it was an overreaction for the sp to hit 60p just as it has been for it to fall to 3p ... there was never a reward for SCIB1 results ...However the IP here only ever increased .. really when I say this is a Poundland BioNTech(mcap $16 billion) I mean it... the team science here has built a pipeline to fill a pharma... a Big pharma... we are in a share that has no product of no platform of the pipeline valued... that may change soon but even if it does that will just be one.... when some one can come here and explain how Juno and Kite went for the $billions they did when someone can come and say how CI are worth what they are.... and then say but scancell nah they have not the assets to rival and even eclipse those values then I may listen but no one ever has( they did recently say scancell need to sell out at any offer 23p though))) ... because Immunotherapy is a revolution in its early days a market that is making itself...values are being written by results...

TBF it was obviously a copy and paste

Look at it like this ... 'eggs in basket' scancell has 3 platforms and many eggs in the basket it can, in theory, treat both early-stage and late-stage cancers in multiple indeed possibly all 'solid' tumours targets( cold tumours turned into hot) it can go beyond cancer into autoimmune diseases and viruses it can do it in a non-toxic and easily administered affordable way... It now has the funds to prove this any one successful product out of the pipeline could give an mcap above £1 billion.... risk/reward?

Yes, so Cliff who is in late-stage deal talks we presume with Bio 1 of the 3 research collaborators... (it'll be interesting to know whom they are) said a pre-clinical MaB asset can expect to get low £millions upfront with 200- 300 million in milestone payments ... I presume with on commercialisation a % of that too... he then went on to say however that is not necessarily the deal scancell would be doing on the seemingly one asset talks are around and that AvidiMab is a slightly different business model ...We wait to see what deal comes, I myself thought ahh maybe ours will not be a 'standard' deal as in AvidiMab will be involved and may be licensed for other MaBs on bio 1's pipeline ...
All of scancell's pipeline is open for partnership deals... We saw how fast Astra wanted to get involved with Oxfords vaccine I think Covidity getting funds makes that and indeed the whole ImmunoBody platform especially if we are now beyond third party electroporation devices ripe for some pharma interest.... moditope... can pharma really ignore it? do not discount a modi1 deal however now fully funded for the trial it may well be scancell will keep that goose that may lay the endless golden eggs completely to itself.... it is going to be an interesting 2021 here that is for sure!....BTW the Borese nibbler has been active these days too

http://www.pharmatimes.com/news/uk_increases_covid-19_vaccine_manufacturing_capacity_1346214#:~:text=According%20to%20a%20statement%20released,based%20in%20Wrexham%2C%20North%20Wales.

moon certainly I'm in that camp... I never expected to this journey to be so long but the size of the prize has only grown... I said to myself I'm only out of here on the day I think the sp is inflated to the IP (or we get swallowed up of course ) we are miles away from that however we may not be years away, in fact, it could even happen by next year if modi 1 does what it could this price is going to look like one of the biggest missed opportunities in invested.... mark me words!

Yeah, 10% traders will be all over this now and a few with significant longterm holders maybe slicing a long waited for bit of profit off their holdings however I reckon most will be wanting to retain a solid stake and others waking up to scancell will be wanting to build theirs whilst they can at these prices as once the deal/s and or positive newsflow rolls in (as expected) now scancell is fully funded and Covidity has Gov backing it looks likely we are only going one-way sp wise and that is up... of course now I've said that red day tomorrow lol

Well, there are multiple reasons for the rise lol in no particular order fully funded for 2 trials one of which is a 4 in one that could by itself cause a cancer treatment revolution and be extending into many more possibly 10 more! targets if the moditope mechanism is able to be kicked in fully and as effectively as in pre-clincal models ... plus we all know you get an idea of 'is it working' or not quite fast on a therapeutic dose... SCIB1 combo trial which could prove ImmunoBody to be a perfect synergy partner for CI's and further boosting the value of ImmunoBody IP... Covidity it has backing now!... It could also attract possible pharma partner interest I think...And a whole new way of delivering ImmunoBody is being developed by the team getting away from the need for third-party electroporation devices and all the problems that layered upon the platform... And Avidimab/Glycans.... We have been told to be expecting our first deal there and possibly v soon a deal done after a lot of research done by the potential partner... it could be first of many and then there, then there is TCR and BioNTech and indeed potential partnership deals throughout the pipeline plus Lindy surprises!.. finally iwe may well be n the right place at the right time....... err best add a 'tick-tock' for old times sake lol

The forecasted value of the checkpoint inhibitors is according to Business wire :'Global Immune Checkpoint Inhibitors Market Outlook 2022, the global immune checkpoint inhibitors market is anticipated to cross US$ 25 billion by 2022.'

Yup so one type of immunotherapy -checkpoint inhibitors which we all here know of its many issues and that no one company owns that class of Immunotheraphy... well

'Moditope® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.'

Next year first product modi 1 of scancells fully owned and patented moditope platform goes into trial in 4 cancer targets...
It has the potential to eclipse the checkpoint inhibitor market... once you work that one out .... 15p :)

They may have been talking in German :)

It is a baby bio with a pipeline that could fill a pharma it really is as simple as that and deal/s are coming and some data is in (positive) and more will come next year and many products in those pipelines could become blockbusters .... Also now moving beyond cancer of which scancell can target many cancer targets other techs can't... 'turning cold tumours hot'.... this re-rating is not undeserved or without sensible reason... Redmile and Vulpes are not daft!

Poundland BioNTech buy its stock up whilst you can!

Gosh at this rate we might be doing 20p dance!

nana the famous 'freebies' ..... lol that mean't the holders of those bottom drawer shares could not stay away on a day in day out obsession of all things scancell ... the draw of the bottom draw :)

I'd feel a whole lot smarter if the sp was over a quid already lol... A ways to go yet and though I like to think below 10p is behind us now .....nothing is certain let's get some more clear blue and hopefully with some more news based depth to it

Well from where we were and the journey to get here I think we are all in a far better situation than we were and Lindys original 'tenfold or bust' I think has changed very favourably not sure what she would give as a figure now but I know she knows the potential commercial value of her works .....

'One company chief optimistic about raising funds even in today’s dire markets is cancer expert Professor Lindy Durrant of Nottingham University, who heads PLUS-quoted Scancell, a developer of cancer vaccines. The company, a spin-off from the university, bases the vaccines on its patented ‘ImmunoBody’ platform, and is researching novel vaccines for melanoma, with a target of reaching Phase 1 clinical trials next year.‘We need to show the vaccines work on patients,’ explains Durrant, ‘but trials, tests and marketing are expensive.’ So, after raising £6 million in various stages from private individuals and venture capital trusts, she took Scancell to PLUS quoted in September, raising £1.5 million at 60p in the process.‘We’ll need to raise a bit more for clinical trials’, reflects Durrant, who is advised by St Helen’s Capital. Finding PLUS’s terms more acceptable than those the venture capital trusts wanted to impose, she sounds reasonably confident about the next stage. ‘We now have three years of trials, with no big news flow till then’, she points out, ‘and I’ve told investors it’s either a tenfold gain or nothing.’

https://www.growthcompany.co.uk/durrants-high-stakes-game-991967/

Ahh, I get you now.... those very flexible and endlessly frustrating timelines that became a very bad joke here... well at least now being fully funded to get SCIB1 combo and most importantly modi1 over the line .... recruitment permitting we ought to see that all-important data coming in next year...

I'm not sure what you mean by 'developed the science' Ivy? maybe you have misworded it only all these years scancell have been adding to the IP non stop ... and really developing the science ... too many examples to just pick one but lets just use the recent one.. peptide nano delivery of ImmunoBodies... potentially massive and being funded by the Gov :) ... yeah if you mean translating that development and the added IP into SP scancell has not had much joy it seems to be changing now as maybe finally that long-awaited for penny is dropping as to just what potential scancell has in its pipeline and it is beginning to attract the right attention

Certainly, negative posters have gone after every possible negative included questioning if the science is any good and called Lindy a part-timer and lifestyle CSO etc ...

My main concern at this point is dosing enough patients before the SCIB1 goes off!